Asset Details
Do you wish to reserve the book?
Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II
Do you wish to request the book?
Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II
2016
Overview
Cardiac hypertrophy is an important risk factor for heart failure. Epidermal growth factor receptor (EGFR) has been found to play a role in the pathogenesis of various cardiovascular diseases. The aim of this current study was to examine the role of EGFR in angiotensin II (Ang II)‐induced cardiac hypertrophy and identify the underlying molecular mechanisms. In this study, we observed that both Ang II and EGF could increase the phospohorylation of EGFR and protein kinase B (AKT)/extracellular signal‐regulated kinase (ERK), and then induce cell hypertrophy in H9c2 cells. Both pharmacological inhibitors and genetic silencing significantly reduced Ang II‐induced EGFR signalling pathway activation, hypertrophic marker overexpression, and cell hypertrophy. In addition, our results showed that Ang II‐induced EGFR activation is mediated by c‐Src phosphorylation. In vivo, Ang II treatment significantly led to cardiac remodelling including cardiac hypertrophy, disorganization and fibrosis, accompanied by the activation of EGFR signalling pathway in the heart tissues, while all these molecular and pathological alterations were attenuated by the oral administration with EGFR inhibitors. In conclusion, the c‐Src‐dependent EGFR activation may play an important role in Ang II‐induced cardiac hypertrophy, and inhibition of EGFR by specific molecules may be an effective strategy for the treatment of Ang II‐associated cardiac diseases.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Animals
/ Cardiomegaly - chemically induced
/ Cardiotonic Agents - pharmacology
/ Cardiotonic Agents - therapeutic use
/ c‐Src
/ Drug Evaluation, Preclinical
/ Epidermal Growth Factor - physiology
/ epidermal growth factor receptor
/ Epidermal growth factor receptors
/ Extracellular signal-regulated kinase
/ Fibrosis
/ Heart
/ Kinases
/ Myocytes, Cardiac - drug effects
/ Myocytes, Cardiac - physiology
/ Original
/ Proteins
/ Quinazolines - therapeutic use
/ Rats
/ Receptor, Epidermal Growth Factor - antagonists & inhibitors
/ Receptor, Epidermal Growth Factor - genetics
/ Receptor, Epidermal Growth Factor - metabolism
/ Studies
